J&J will pay Arkansas $7.8 million to settle Risperdal’s diabetes risk
Posted on Tuesday, June 9th, 2015 at 3:16 pm by Williams Hart
Johnson & Johnson (J&J) has entered a settlement agreement worth $7.8 million over the state of Arkansas’ allegations that the company misled patients and doctors about the diabetes risk of its anti-psychotic drug Risperdal, Bloomberg Business reported on May 22.
The settlement, which ended close to eight decades of legal brawl over Risperdal’s diabetes risk, came amid various state lawsuits filed against the company. Risperdal is blamed for a myriad of different adverse effects, including gynecomastia, or the enlargement of breast tissue in males. But despite issues of side-effects, an emailed statement by a company spokesperson said the company’s recent settlement with Arkansas doesn’t mean admittance of liability.
Facing large pharmaceutical companies in a fight for justice and compensation requires not just legal expertise and resources, but also tenacity and will power. At Williams Hart, we handle each of our cases with diligent assertiveness and compassion. Call us at (713) 352-7071 to learn more about how we might be able to help you file a case if ever you’ve been hurt by a defective drug.